Market Intelligence, Clinical Progress, and High-Purity Reagents for Hepatocellular Carcinoma and Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FGFR4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FGFR4 ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed. | View FGFR4 Products |
| Gene Delivery | FGFR4 Promise-ORF / Lentivirus. Full-length human FGFR4 ORF for stable cell line generation. | View FGFR4 Products |
| Benchmark Ab | Anti-FGFR4 (Recombinant Reference Clone). Recombinant positive control for binding and affinity assays. | View FGFR4 Products |
| Validator | FGFR4 siRNA Set. For knockdown verification and specificity controls. | View FGFR4 Products |
| Related Target A | FGFR1. Critical paralog for selectivity counter-screening and off-target liability assessment. | View FGFR1 Products |
| Related Target B | FGF19. Primary ligand for functional cell-based assays and co-complex studies. Drives oncogenic signaling in HCC. | View FGF19 Products |
| Related Target C | KLB (Klotho Beta). Essential co-receptor for FGF19-FGFR4 binding; useful for complex-based drug development. | View KLB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pan-FGFR Cross-Reactivity (Toxicity) | Homolog panel proteins (FGFR1/2/3) strictly verified by mass spec for counter-screening. |
| Cross-Species Evaluation | Human/Mouse/Cyno FGFR4 ortholog proteins available with >95% purity. Sequence verified. |
| Resistance Mutation Screening | Mutant Recombinant Proteins (e.g., V550L gatekeeper mutant) and custom kinase domain mutants available for resistance profiling. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included. |
| False Positives | Sequence-verified siRNA included for specificity checks. |
Live FGFR4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FGFR4 therapeutics is intensifying, with major players shifting focus from traditional pan-FGFR inhibitors to highly selective FGFR4 antagonists. First-generation therapies for hepatocellular carcinoma (HCC) are reaching the clinic, yet acquired resistance mutations (like V550L) are emerging, driving the next wave of R&D. Beyond small molecules, the landscape is expanding into antibody-drug conjugates (ADCs), bispecific engagers, and proteolysis-targeting chimeras (PROTACs) to fully exploit FGFR4-driven oncogenic signaling in HCC and other solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Novartis (Fisogatinib), Blueprint Medicines (Roblitinib), Bayer, H3 Biomedicine | HCC, Solid Tumors | Selectivity Assay: Need FGFR1/2/3/4 homolog panel and mutant vs WT proteins for resistance profiling. |
| ADC | Early-stage biotechs, ADC specialists | HCC, Breast Cancer | Internalization Assay: Need high-purity ECD-Fc and stable lentivirus-expressing cell lines. |
| Monoclonal / Bispecific | U3 Pharma (Daiichi), Emerging immuno-oncology developers | Advanced Solid Tumors | Affinity & Heterodimer Validation: Need cross-reactive Abs and ligand competition assays. |
Key Structural Features and Natural Variants
FGFR4 (UniProt P22455) contains an extracellular region with three Ig-like C2-type domains (Ig-like C2-type 1, 2, 3) that mediate ligand binding and receptor dimerization. Key natural variants include dbSNP entries rs1966265, rs376618, and rs55675160, which may influence receptor activity or drug response. Understanding these features is critical for designing selective binders and anticipating inter-individual variability.